Listen to this article · 7 min listen

To get a new diagnostic technology into a health system as a billable service, you have to prove it’s cost-effective, not just that it works clinically. This evidence, carefully documented and published in peer-reviewed journals, is what gives health system finance leaders and medtech analysts the confidence to price and integrate new AI healthcare applications. It’s what connects a good clinical idea to something that actually makes economic sense.

HeartFlow’s Nasdaq Listing and the Cost-Effectiveness Blueprint

HeartFlow’s story is the perfect example of how a diagnostic analysis gets turned into a priced service and, eventually, a big market valuation. Instead of just talking about usage, HeartFlow built its case on a massive body of cost-effectiveness analysis. Their strategy is obvious from their publication record: over 600 peer-reviewed articles and studies on more than 500,000 patients PubMed search for HeartFlow FFRCT cost-effectiveness. All this evidence helped them get through the regulatory and reimbursement maze, including a thumbs-up from NICE. The financial markets paid attention to this groundwork. HeartFlow listed on the Nasdaq in August 2025, raising $364 million at a $3.07 billion market cap. This validation from the public market was a direct response to the economic argument they painstakingly built through all that cost-effectiveness research. For any CFO in a health system, HeartFlow’s path is the blueprint: the price for a new diagnostic is anchored to its proven ability to deliver real cost savings and better patient outcomes, all documented by independent research.

Deconstructing the Cost-Effectiveness Analysis for Diagnostic AI

When you’re doing a cost-effectiveness analysis for a diagnostic AI, you’re doing more than just proving its accuracy. You’re quantifying its economic value proposition by comparing the costs and health outcomes of the AI pathway against the old standard of care. This means digging into a few key areas:

  • Direct Medical Costs: This is the cost of the test itself, but also the subsequent invasive procedures you avoided, the fewer hospitalizations, and changes in medication. A cardiac AI tool that lets you confidently rule out obstructive coronary artery disease, for example, means you can skip a lot of unnecessary and expensive invasive angiograms.
  • Indirect Costs: These are harder to nail down but are just as real. Think about productivity losses from people being sick or in recovery. A more efficient diagnostic that leads to faster, more targeted treatment gets people back to their lives (and jobs) sooner.
  • Clinical Outcomes: The analysis has to show that clinical outcomes are better or at least the same. We’re talking about fewer major adverse cardiac events (MACE), better quality of life, or lower mortality. The combination of better outcomes and lower costs is what makes a cost-effectiveness argument so powerful.
  • Resource Utilization: How does the diagnostic AI affect your use of hospital beds, OR time, and specialist consults? (These are the questions your COO is asking). AI-driven efficiencies here can lead to huge savings. The HeartFlow FFRCT Cost-Effectiveness Analysis is the gold standard for pricing a diagnostic pathway because it systematically answered all these questions. It showed that even if the initial test costs something, the downstream savings and improved patient care are worth it many times over. This is the kind of granular data finance leaders need to justify buying in and that medtech analysts need to see long-term market potential.

    Cleerly: A Peer in Cardiac Imaging with a Similar Economic Question

Cleerly is playing in the same sandbox as HeartFlow. Its plaque analysis program is built on the same coronary CT modality. This means Cleerly has to answer the exact same, fundamental economic question: how does your advanced diagnostic capability translate into measurable cost-effectiveness and, eventually, a priced service? That’s exactly what their CERTAIN trial is about. While the specific findings are still being analyzed, the fact that the trial even exists shows the industry gets it now: being clinically superior isn’t enough. The trial is designed to generate the hard evidence showing how its detailed plaque analysis improves patient management and cuts healthcare spending compared to standard CT angiography. The company has raised over $385 million, which shows investors are confident it has the potential to answer this economic question with compelling data and grab significant market share SEC filings for Cleerly funding rounds, Cleerly Series C extension funding round December 2024. For medtech analysts, the parallel is obvious. Both companies use AI to get more actionable information from routine cardiac scans. Both also know that the only way to get widespread adoption and make real money is to quantify the return on investment for health systems. You have to be able to draw a straight line from a diagnostic finding to a change in patient management that results in better outcomes and lower costs.

The Revenue Record as the Category Benchmark

At the end of the day, the real proof that a diagnostic analysis pathway has become a durable business is its revenue. HeartFlow’s reported revenue of $176 million for the 2025 fiscal year, with 40% year-over-year growth and a projection of $246 million to $250 million for 2026, turned its original cost-effectiveness argument into a benchmark for the entire category. Numbers like that show the market has fully embraced the value proposition. For health system finance leaders, this revenue isn’t just a business success story. It’s a signal of a strong, sustainable billing path for a high-value service. It means the cost-effectiveness analysis worked, leading to adoption and, critically, reimbursement. Medtech analysts see these figures as the key indicators of market penetration, scalability, and the long-term viability of the tech. It confirms that the money spent on clinical evidence and cost-effectiveness studies brings a real, tangible return Investor relations reports for HeartFlow 2026 fiscal year. Getting from a new AI application to a multi-million dollar revenue stream is a grind through peer-reviewed data, regulatory approvals, and building a compelling economic argument that aligns clinical benefit with financial reality. A diagnostic analysis pathway becomes a durable business when the cost-effectiveness evidence and the billing path finally line up. The stories of companies like HeartFlow and Cleerly show that this rigorous economic analysis is the fundamental pivot that turns a modern diagnostic technology into a priced, and highly valuable, service in the healthcare system.

Frequently Asked Questions

What is the primary factor, beyond clinical efficacy, that determines the financial viability and pricing of a novel AI diagnostic service within a health system?

The primary factor is a rigorously demonstrated cost-effectiveness analysis. This analysis provides the pivotal evidence needed for health system finance leaders and medtech analysts to confidently price and integrate new AI healthcare applications, bridging clinical innovation with sustainable economic impact.

What key components should a comprehensive cost-effectiveness analysis for a diagnostic AI solution include?

A comprehensive cost-effectiveness analysis should quantify direct medical costs, such as the test itself and avoided procedures, and consider indirect costs like productivity losses. It must also demonstrate superior or equivalent clinical outcomes and analyze the impact on resource utilization, like hospital bed or operating room time.

How did HeartFlow’s approach to market validation provide a blueprint for pricing AI diagnostics?

HeartFlow built its market validation on extensive cost-effectiveness analysis, supported by over 600 peer-reviewed articles and 500,000 patients studied. This robust evidence underpinned its successful regulatory and reimbursement navigation, demonstrating that proven cost savings and improved patient outcomes are the financial anchor for pricing diagnostic analysis pathways.

Why is demonstrating cost-effectiveness crucial for investor confidence and market adoption of AI diagnostics, as seen with Cleerly?

Demonstrating cost-effectiveness is crucial because clinical superiority alone is insufficient for widespread adoption and financial success. Companies like Cleerly, through trials like CERTAIN, aim to provide robust evidence that their advanced diagnostics translate into measurable cost savings and improved patient management, which is essential for investor confidence and market integration.